Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scientific Inc. reports developments tied to computerized drug delivery instruments for dental and medical applications. The company’s Dynamic Pressure Sensing technology supports pressure-guided injection and fluid-aspiration procedures, including dental anesthesia delivery through The Wand STA system and medical applications such as CompuFlo for controlled epidural injections.
Recurring news themes include financial results, business-update calls, commercialization programs, physician and dental-practice adoption, distributor and reimbursement infrastructure, international product registrations, disposable utilization, operating expense initiatives, and capital actions involving common stock and warrants.
Milestone Scientific (NYSE:MLSS), a developer of computerized drug delivery instruments, has appointed Eric C. Hines as its new Chief Executive Officer. Hines brings over 25 years of leadership experience in scaling sales-driven enterprise software companies, most recently serving as President of North America at Ex Libris where he doubled annual revenue from $50M to $100M.
The appointment comes at a crucial time as Milestone Scientific advances its CompuFlo® technology, having secured Medicare Part B payment rates under CPT® code 0777T and initial commercial insurance payments. Hines' experience in healthcare and track record of commercial expansion positions him to drive adoption of the company's technology in medical and dental markets while pursuing new clinical indications and global opportunities.
Milestone Scientific (NYSE:MLSS) has announced the commercial launch of its CompuFlo® Epidural System at The Painless Center in Tenafly, New Jersey. The center is led by Dr. Chi-Shin Jason Chiu, a double board-certified physician in Pain Management and Anesthesiology.
The CompuFlo system leverages the company's proprietary DPS Dynamic Pressure Sensing® technology, providing real-time feedback for accurate epidural space identification. Clinical studies have demonstrated the system's ability to reduce false loss of resistance, minimize complications, and improve epidural procedure success rates.
This deployment is part of Milestone Scientific's broader strategy to expand the adoption of CompuFlo across U.S. and international markets.
Milestone Scientific (NYSE: MLSS) has appointed Shanth Thiyagalingam to its Board of Directors, effective May 14, 2025. Thiyagalingam, currently CEO of PainTEQ, brings over 20 years of global leadership experience in medical devices and pharmaceuticals. This strategic appointment supports Milestone's expansion of its CompuFlo® Epidural System, particularly following recent favorable Medicare Part B payment rates for CPT code 0777T and FSS contract award.
At PainTEQ, Thiyagalingam led the company's growth from startup to market innovator, securing a Category 1 CPT code for the LinQ procedure. His extensive experience includes leadership roles at Abbott, where he managed APAC Neuromodulation operations, Nevro, Stryker, and St. Jude Medical. He holds a Bachelor of Medical Science, Master's in Marketing Management, and MBA.
Milestone Scientific (NYSE: MLSS) reported financial results for 2024, showing revenue of $8.6 million, down from $9.8 million in 2023. Despite the revenue decline, the company highlighted positive developments including Medicare reimbursement expansion for its CompuFlo® Epidural System across multiple U.S. states and a Federal Supply Schedule contract.
The company's U.S. e-commerce platform for dental products generated $5.1 million in revenue, up from $4.8 million in 2023. International revenue decreased to $3.4 million. Gross profit was $6.4 million, down from $6.8 million in 2023. Operating loss improved to $6.8 million from $7.1 million, while net loss decreased to $4.7 million ($0.06 per share) from $6.9 million ($0.10 per share) in 2023.
The company ended 2024 with $3.3 million in cash, $5.5 million in working capital, and no debt, while reporting strong Q1 2025 initial performance and positive outlook.
Milestone Scientific (NYSE: MLSS) has announced that InfiniSurg, , a New Jersey-based ambulatory surgery center, has adopted its CompuFlo® Epidural System for clinical practice. The system will be operated by Dr. Roman Kosiborod, DO, who brings over 20 years of experience in interventional pain management and ambulatory anesthesia.
The order was received through Milestone's distributor, Axial Biologics. The CompuFlo® system utilizes Dynamic Pressure Sensing Technology® to precisely identify the epidural space, providing real-time visual and audible feedback during needle placement. This technology aims to reduce complications such as dural puncture while improving procedural efficiency and patient safety.
Milestone Scientific (NYSE: MLSS) announced the commercial implementation of its CompuFlo® Epidural System at Pain Doctors Medical , following a successful evaluation by Dr. Ilana Etelzon. The system, which employs proprietary Dynamic Pressure Sensing Technology®, provides real-time verification of epidural needle placement to enhance patient safety and procedural efficiency.
The implementation follows the recent Medicare price assignment for the CompuFlo® system, which is helping drive broader accessibility across interventional pain management centers. The technology offers real-time feedback for needle placement confirmation, improving procedural accuracy and safety in pain management procedures.
Milestone Scientific (NYSE: MLSS) announced the commercial rollout of its CompuFlo® Epidural System at Advanced Spine and Pain Management, following a successful pilot program with Dr. Varinder Dhillon. The implementation takes place at SurgiCore Montvale, one of 12 SurgiCore centers in the NY/NJ metro area, suggesting potential for network expansion.
The company reports increasing adoption of the system following a recent Medicare price assignment. The CompuFlo® Epidural System, powered by Dynamic Pressure Sensing Technology®, provides real-time feedback for accurate needle placement during epidural procedures, reducing complications associated with traditional techniques.
Dr. Dhillon praised the system's precision and reliability in improving patient care and procedural efficiency. Neal Goldman, Chairman and Interim CEO, highlighted the growing traction within the healthcare community, particularly among pain management clinics nationwide following the Medicare price assignment.
Milestone Scientific (NYSE: MLSS), a developer of computerized drug delivery instruments for painless and precise injections, has announced its participation in The Benchmark Company's 13th Annual Discovery One-on-One Investor Conference. The event will take place on December 11th, 2024 at the New York Athletic Club in New York City.
CEO Arjan Haverhals and Chairman Neal Goldman will represent the company, with Haverhals conducting one-on-one meetings with investors and analysts throughout the conference day. The conference provides emerging growth companies the opportunity to connect with institutional and individual investors in a unique format.
Milestone Scientific has secured Federal Supply Schedule (FSS) approval for its CompuFlo® Epidural System, enabling pre-vetted contractor status with pre-negotiated pricing. The contract has a potential duration of up to 20 years, including extensions. The FSS designation opens significant opportunities within federal healthcare systems, including the Department of Defense, Veterans Affairs, and Indian Health Service. The CompuFlo® system uses patented Dynamic Pressure Sensing Technology® for accurate needle placement during epidural procedures. The contract provides access to the VHA's network of 1,380 facilities serving 9.1 million veterans, the Military Health System's 9.5 million beneficiaries, and the IHS's 687 facilities serving 2.8 million American Indians and Alaska Natives.